Thursday, 5 November 2026European Markets

GPE GROUP PIZZORNO Stock Bullish By 29% In The Last 21 Sessions

Loading stream...

(vianews) - shares of gpe group pizzorno (cac 40: gpe.pa) jumped by a staggering 29.86% in 21 sessions from €44.2 to €57.40 at 17:52 est on tuesday, following the last session's downward trend. cac 40 is rising 0.18% to €7,213.92, following the last session's downward trend.

about gpe group pizzorno

groupe pizzorno environnement provides environmental services primarily in france. it engages in the production and recycling of secondary raw materials; development of technologies and services for the recovery of bio-waste; production of heat and electricity from waste treatment; and processing and collection of household waste, as well as offers cleanliness services. groupe pizzorno environnement was founded in 1974 and is headquartered in draguignan, france.

earnings per share

as for profitability, gpe group pizzorno has a trailing twelve months eps of €5.18.

pe ratio

gpe group pizzorno has a trailing twelve months price to earnings ratio of 11.08. meaning, the purchaser of the share is investing €11.08 for every euro of annual earnings.

volume

today's last reported volume for gpe group pizzorno is 136 which is 74.62% below its average volume of 465.

volatility

gpe group pizzorno's last week, last month's, and last quarter's current intraday variation average was 1.83%, 1.53%, and 1.57%.

gpe group pizzorno's highest amplitude of average volatility was 2.56% (last week), 2.22% (last month), and 1.57% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, gpe group pizzorno's stock is considered to be oversold (<=20).

more news about gpe group pizzorno (gpe.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com